Multi-omics profiling highlights karyopherin subunit alpha 2 as a promising biomarker for prognosis and immunotherapy respond in pediatric and adult adrenocortical carcinoma

Yihao Chen Shumin Fang Chuanfan Zhong Shanshan Mo Yongcheng Shi Xiaohui Ling Fengping Liu Weide Zhong Junhong Deng Zhong Dong Jiahong Chen Jianming Lu a Department of Andrology,Guangzhou First People's Hospital,Guangzhou Medical University,Guangzhou,Chinab Department of Urology,Huizhou Central Hospital,Huizhou,Chinac Science Research Center,Huizhou Central Hospital,Huizhou,Chinad Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou,Chinae Reproductive Medicine Center,Huizhou Central Hospital,Huizhou,Chinaf State Key Laboratory of Quality Research in Chinese Medicine,Macau University of Science and Technology,Taipa,Chinag Department of Urology,Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics,Guangzhou First People's Hospital,Guangzhou Medical University,Guangzhou,China
DOI: https://doi.org/10.1080/07853890.2024.2397092
IF: 5.348
2024-12-04
Annals of Medicine
Abstract:Purpose Adrenocortical carcinoma (ACC) afflicts both pediatric and adult populations and is characterized by dismal prognosis and elevated mortality. Given the inconsistent therapeutic benefits and significant side effects associated with the conventional chemotherapy agent, mitotane, and the nascent stage of immunotherapy and targeted treatments, there is an urgent need to identify novel prognostic biomarkers and therapeutic targets in ACC.
medicine, general & internal
What problem does this paper attempt to address?